UCN-01 (cas 112953-11-4), an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily
-
Add time:08/05/2019 Source:sciencedirect.com
A selective PKC inhibitor, UCN-01, was shown to exhibit anti-tumor activity in vitro and in vivo. We investigated UCN-01 with respect to isozyme-specific PKC inhibition using purified recombinant or rabbit brain PKC isozymes, cPKCα, β and γ, nPKCδ, ϵ and ν, and aPKCζ. Of the PKC isozymes examined, cPKCα was inhibited by UCN-01 most effectively (Ki = 0.44 nM), suggesting cPKCα is the prime candidate for the physiological target of UCN-01. The Ki values of UCN-01 estimated from Dixon plots for cPKC isozymes are approximately 1 nM, whereas the Ki values for nPKC isozymes are about 20 nM. Moreover, the Ki value for aPKCζ is 3.8 μM. Thus, UCN-01 discriminates between PKC subfamilies. In addition, the inhibitory effects of staurosporine, H7, and calphostin C on aPKCζ were examined and compared with those for cPKCα.
We also recommend Trading Suppliers and Manufacturers of UCN-01 (cas 112953-11-4). Pls Click Website Link as below: cas 112953-11-4 suppliers
Prev:Controlled release of a protein kinase inhibitor UCN-01 (cas 112953-11-4) from liposomes influenced by the particle size
Next:Enantiospecific synthesis of (6R,7S,8aR)-dihydroxyindolizidine and ((6R,7R) (cas 112953-21-6),8S,8aR)-trihydroxyindolizidine from D-glucose.) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Controlled release of a protein kinase inhibitor UCN-01 (cas 112953-11-4) from liposomes influenced by the particle size08/04/2019
- UCN-01 (cas 112953-11-4) in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium08/03/2019
- Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01 (cas 112953-11-4), in human plasma or urine08/02/2019
- AG490 influences UCN-01 (cas 112953-11-4)-induced cytotoxicity in Glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation08/01/2019
- Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 (cas 112953-11-4) in human plasma07/31/2019
- MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 (cas 112953-11-4) by exacerbating radiation-induced aberrant mitosis07/30/2019
- The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01 (cas 112953-11-4), induces fragmentation: Possible role of metalloproteinases07/29/2019
- Celecoxib Enhances the Radiosensitizing Effect of 7-Hydroxystaurosporine (UCN-01 (cas 112953-11-4)) in Human Lung Cancer Cell Lines07/28/2019
- The combination of UCN-01 (cas 112953-11-4) and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK07/27/2019